Contract manufacturing organization

Contract Development and Manufacturing Organization (CDMO) Outsourcing Market|17000+ Technavio Reports

Retrieved on: 
Thursday, June 24, 2021
Articles, Economy, Business, Financial technology, Economic globalization, Offshoring, Contract manufacturing organization, Pharmaceutical industry, Information technology management, Outsourcing, Benchmarking, Crowdfunding

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43489

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43489
    Contract Development and Manufacturing Organization (CDMO) Outsourcing Market 2021-2025: Vendor Analysis and Scope
    To help businesses improve their market position, the contract development and manufacturing organization (CDMO) outsourcing market provides a detailed analysis of around 25 vendors operating in the market.
  • The report also covers the following areas:
    The growing pharmaceutical industry is likely to emerge as one of the primary drivers of the market.
  • Backed with competitive intelligence and benchmarking, our research reports on the contract development and manufacturing organization (CDMO) outsourcing market are designed to provide entry support, customer profile & M&As as well as go-to-market strategy support.
  • Contract Development and Manufacturing Organization (CDMO) Outsourcing Market 2021-2025: Key Highlights
    Related Reports on Consumer Discretionary Include:
    Global Alternative Finance Market- The alternative finance market is segmented by type (P2P lending, crowdfunding, and invoice trading) and geography (APAC, North America, Europe, South America, and MEA).

Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections

Retrieved on: 
Wednesday, June 23, 2021
Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Samsung, Samsung Biologics, Food and Drug Administration, Contract manufacturing organization, Biopharmaceutical

The innovative digital solution was developed and implemented at Samsung Biologics a year ago in the wake of the pandemic and has since been successfully utilized in over 50 virtual regulatory and client audits and inspections and counting.

Key Points: 
  • The innovative digital solution was developed and implemented at Samsung Biologics a year ago in the wake of the pandemic and has since been successfully utilized in over 50 virtual regulatory and client audits and inspections and counting.
  • John Rim, CEO of Samsung Biologics, said of the inspections, "While we have had many successful regulatory inspections in the past, these recent approvals, are meaningful milestones for Samsung Biologics.
  • The FDA issued a new recommendation in April providing guidance on remote inspections ("Remote Interactive Evaluations") in light of COVID-19, suggesting that the FDA may continue to use remote inspections to supplement on-site audits post-pandemic.
  • Samsung Biologics (KRX: 207940.KS) is a fully integrated CDMO offering state-of-the-art contract development, manufacturing, and laboratory testing services.

Recro Appoints Laura L. Parks, Ph.D. to Board of Directors

Retrieved on: 
Wednesday, June 16, 2021
Contract manufacturing organization, Pharmaceutical industry, Advisory board

She currently serves on the advisory board of Lindy BioSciences, a Durham, NC-based development-stage protein therapeuticformulations company.

Key Points: 
  • She currently serves on the advisory board of Lindy BioSciences, a Durham, NC-based development-stage protein therapeuticformulations company.
  • We are happy to add Laura and her broad biopharma CDMO industry experience to our board of directors.
  • We welcome Laura to the Recro team and look forward to the key contributions that she will make to the companys ongoing success.
  • Recro (NASDAQ: REPH ) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing.

Cytovance Biologics announces Plasmid DNA Manufacturing: An Optimized Platform Process Webinar

Retrieved on: 
Monday, June 14, 2021
Life sciences, Branches of biology, Biology, Molecular biology, Pharmaceutical industry, Gene delivery, Biotechnology, DNA, Plasmid, Biopharmaceutical, Contract manufacturing organization, DNA supercoil

OKLAHOMA CITY, June 14, 2021 (GLOBE NEWSWIRE) -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process.

Key Points: 
  • OKLAHOMA CITY, June 14, 2021 (GLOBE NEWSWIRE) -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process.
  • Our featured speakers will discuss strain selection, plasmid optimization, media composition and fermentation conditions necessary to produce high quality supercoiled plasmid DNA.
  • The demand for large quantities of high-quality supercoiled plasmid DNA (Sc-pDNA) has increased over the years due to its primary role in gene therapy.
  • The platform purification process developed by Cytovance addresses the main challenges in large scale manufacturing of pDNA such as scalability, quantity and quality.

Forge Biologics to Present at 2021 BIO Digital Conference

Retrieved on: 
Thursday, June 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Life sciences, Articles, Biotechnology, Pharmaceutical industry, Biopharmaceutical, Pharmacy, Contract manufacturing organization, Gene therapy, Biotechnology Innovation Organization, GenScript Biotech, WuXi Biologics

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that it will be delivering a company presentation at BIO Digital, hosted by the Biotechnology Innovation Organization, being held June 10-11 and 14-18, 2021.

Key Points: 
  • Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that it will be delivering a company presentation at BIO Digital, hosted by the Biotechnology Innovation Organization, being held June 10-11 and 14-18, 2021.
  • Forge will be taking meetings during BIO Digital.
  • Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company.
  • By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

North American Healthcare CDMO (Contract Development and Manufacturing Organization) Market 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Pharmaceutical, Health, Medical devices, Contract manufacturing organization, Pharmaceutical industry, Health care in the United States, Marketplace

The North American healthcare CDMO market is estimated to grow significantly during the forecast period.

Key Points: 
  • The North American healthcare CDMO market is estimated to grow significantly during the forecast period.
  • There is a surging demand for innovative drugs and medical devices across the region which has augmented the market growth of the North American Healthcare CDMO market in recent years.
  • Based on geography, the North American healthcare CDMO market is further segregated into the US and Canada.
  • The US is projected to have a considerable share in the North American healthcare CDMO market owing to the presence of major market players and significant investment in drug discovery and development in the country.

Forge Biologics Expands Gene Therapy Leadership Team with Appointment of John Maslowski as Chief Commercial Officer

Retrieved on: 
Thursday, June 3, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Forge, X-Factor, Biopharmaceutical, Contract manufacturing organization

Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.

Key Points: 
  • Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer.
  • Mr. Maslowski brings significant gene therapy manufacturing and development experience to Forge as the Company has expanded its cGMP AAV manufacturing capabilities, including process and analytical development.
  • Mr. Maslowski comes to Forge after serving as the President and Chief Executive Officer of Castle Creek Biosciences, Inc.
  • The gene and cell therapy industry has seen tremendous growth over the past decade, but GMP manufacturing at larger scales remains a challenge, said Mr. Maslowski, Forge Chief Commercial Officer.

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

Retrieved on: 
Wednesday, June 2, 2021
Contract manufacturing organization, Pharmaceutical industry, Antibody Solutions, GenScript Biotech, Life sciences, Biology

Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.

Key Points: 
  • Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.
  • "We are excited to enter into this new relationship with Ligand, which has one of the best antibody discovery platforms in the world," said Brian Min, Ph.D., CEO of GenScript ProBio.
  • GenScript ProBio, already a qualified OmniAb contract research organization (CRO) for antibody discovery services, is now the second contract development and manufacturing organization (CDMO) in China to secure a global license to the transgenic rodent technology of the OmniAb platform.
  • With more than 16 years of experience in custom antibody services for various targets, GenScript ProBio provides a range of immunization methods.

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate

Retrieved on: 
Wednesday, June 2, 2021
Life sciences, Companies, Industry economics), Pharmaceutical industry, Samsung, Samsung Biologics, Biopharmaceutical, Contract manufacturing organization

INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.

Key Points: 
  • INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.
  • Under the terms of the agreement, Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR's drug candidate DSP502, a TIGITxPD1 fusion protein.
  • "We are proud to announce our partnership with KAHR Medical for the production of their novel drug candidate," said John Rim, CEO of Samsung Biologics.
  • "We are very pleased to partner with Samsung BioLogics, which is recognized as a leader in biopharmaceutical process development and manufacturing" saidYaron Pereg, Ph.D., Chief Executive Officer of KAHR.

Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings

Retrieved on: 
Wednesday, June 2, 2021
Pharmaceutical industry, Pharmaceuticals policy, Qualified person, Contract manufacturing organization, Blister pack

GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it has expanded the clinical capabilities of the companys growing Clinical Trial Services (CTS) offerings.

Key Points: 
  • GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Recro; NASDAQ: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it has expanded the clinical capabilities of the companys growing Clinical Trial Services (CTS) offerings.
  • Included among the newly added CTS capabilities are clinical-scale sachet and blister packaging for clinical trial pharmaceuticals.
  • Additionally, Recro has established a relationship with a European Union Qualified Person (QP) for its CTS offerings following a successful review process.
  • This QP has audited the companys facility and stated that Recro meets the relevant GMP manufacturing standards and requirements for clinical trial materials to be used in the EU.